Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies(University of Oxford), Hongchao Pan(University of Oxford), Jon Godwin(Glasgow Caledonian University), Richard Gray(University of Oxford), R. Arriagada(Institut Gustave Roussy), Vinod Raina(DR. B.R.A. Institute Rotary Cancer Hospital), Mirta Abraham(Instituto Cardiovascular de Rosario), Victor Hugo Medeiros Alencar(Hospital Haroldo Juaçaba), A. S. Badran(Cairo University), Xavier Bonfill(Hospital de Sant Pau), Joan Bradbury(Monash University), Michael Clarke(Queen's University Belfast), Rory Collins(University of Oxford), Susan R. Davis(Monash University), Antonella Delmestri(University of Oxford), John Forbes(Breast Cancer Trials), Peiman Haddad(Tehran University of Medical Sciences), Ming‐Feng Hou(Kaohsiung Medical University Chung-Ho Memorial Hospital), Moshe Inbar(Tel Aviv Sourasky Medical Center), Hussein Khaled(Cairo University), Joanna Kielanowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Wing-Hong Kwan, Beela Sarah Mathew(Regional Cancer Center, Thiruvananthapuram), Indraneel Mittra(Tata Memorial Hospital), Bettina Müller, Antonio Nicolucci(Mario Negri Sud Foundation), O Peralta, Fany Pernas, Luboš Petruželka(Charles University), Tadeusz Pieńkowski(European Regional Centre for Ecohydrology), Ramachandran Radhika(Cancer Institute (WIA)), Balakrishnan Rajan(Royal Hospital), Maryna T Rubach(Tata Memorial Hospital), Sera Tort(Hospital de Sant Pau), Gerard Urrútia(Hospital de Sant Pau), Miriam Valentini(Mario Negri Sud Foundation), Yaochen Wang(University of Oxford), Richárd Pető(University of Oxford)
Cited by 2,036Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis